Investors comparing the Vanguard Total Bond Market ETF (BND) and the Schwab U.S. Dividend Equity ETF (SCHD) are really weighing two different answers to the same question: how to build a resilient, income-oriented portfolio. These two funds do not compete directly, nor do they sit in the same sector. BND anchors the fixed-income sleeve of a portfolio with broad U.S. investment-grade debt, while SCHD targets a concentrated basket of high-quality dividend stocks. Understanding their structural differences — asset class, sector exposure, cost, and risk — is essential for anyone making an informed ETF comparison and deciding how these funds fit together in a diversified allocation. I also checked this using Tickeron’s AI Screener to see how the two line up against peers.
BND is a passively managed exchange-traded fund that seeks to track the Bloomberg U.S. Aggregate Float Adjusted Index, a benchmark covering the broad, U.S. dollar-denominated, investment-grade, taxable bond market. The fund holds more than 11,000 individual bonds, so no single position meaningfully moves the portfolio. Its largest exposures are U.S. Treasury securities (roughly 46% of assets), government mortgage-backed securities such as Ginnie Mae and agency pools (about 21%), and investment-grade corporate bonds (about 25%), with smaller allocations to asset-backed and international dollar-denominated debt. BND carries an expense ratio of 0.03%, among the lowest in the industry. Its portfolio has an average duration of roughly six years and an average maturity above eight years, making it a core, intermediate-term bond holding whose total return is heavily influenced by shifts in interest rates and inflation expectations.
SCHD is a passively managed ETF that tracks the Dow Jones U.S. Dividend 100 Index, a rules-based benchmark of U.S. stocks with a record of consistent dividend payments and strong fundamentals. The index screens candidates on four quality factors: cash flow to total debt, return on equity, dividend yield, and five-year dividend growth, then weights the roughly 100 selected names by market capitalization. Top holdings include Texas Instruments (TXN), Procter & Gamble (PG), Coca-Cola (KO), Chevron (CVX), Merck (MRK), Amgen (AMGN), and Home Depot (HD). Sector allocation skews toward healthcare (roughly 21%), consumer staples (about 19%), energy (about 15%), and technology (about 13%). SCHD charges a 0.06% expense ratio and generally offers a dividend yield well above the broad market, positioning it as a large-cap value and income vehicle rather than a growth fund.
The two funds are shaped by opposite macro forces. BND's fortunes hinge on the interest-rate and inflation environment: when yields fall, bond prices rise and duration-sensitive funds outperform; when yields climb, bond prices face headwinds, though higher coupons gradually cushion total return. For SCHD, the relevant backdrop is the equity cycle, particularly the rotation between growth and value styles. Its heavy weighting in healthcare, staples, and energy means SCHD is influenced by pharmaceutical pricing and pipeline developments, consumer spending resilience, and commodity prices. Regulatory scrutiny of healthcare, energy policy shifts, and the path of Federal Reserve rate decisions all feed directly into these funds' relative positioning. Recent market cycles have seen investors reassess dividend and quality strategies as bond yields and inflation expectations fluctuate, keeping both funds in the spotlight.
Over recent months and market cycles, BND and SCHD have delivered sharply different performance profiles. BND's fund performance has tracked the trajectory of Treasury yields, with total return supported by a yield near or above 4–5% in recent periods but pressured when rates have risen. SCHD, by contrast, has been driven by the earnings and dividend growth of its mega-cap value holdings, and its lower-than-market beta has historically moderated drawdowns in risk-off episodes while causing it to lag during growth-led rallies. In relative positioning terms, BND offers stability and predictable income with modest price movement, whereas SCHD offers higher income and capital-appreciation potential alongside meaningfully greater volatility. Because the two occupy different asset classes, their performance is often complementary rather than correlated, making the comparison less about picking a winner and more about allocating across risk.
One thing that stands out when I evaluate funds like these is how helpful Tickeron’s AI Screener can be for quickly comparing characteristics across asset classes. I often run side-by-side scans on expense ratios, sector exposures, and historical volatility to confirm what the data shows before forming a final view.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day moving average for BND crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 35 of 66 cases where BND's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 53%.
BND moved above its 50-day moving average on November 16, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +0.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where BND advanced for three days, in 152 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
BND may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 132 of 245 cases where BND Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The 10-day RSI Indicator for BND moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 12 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 38%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BND as a result. In 40 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 49%.
The Moving Average Convergence Divergence Histogram (MACD) for BND turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 22 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.